Inhalation of Respirable Crystalline Rifapentine Particles Induces Pulmonary Inflammation.
Sign Up to like & getrecommendations! Published in 2017 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.6b00905
Abstract: Rifapentine is an anti-tuberculosis (anti-TB) drug with a prolonged half-life, but oral delivery results in low concentrations in the lungs because of its high binding (98%) to plasma proteins. We have shown that inhalation of… read more here.
Keywords: delivery; rifapentine; rifapentine particles; inhalation ... See more keywords
Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis
Sign Up to like & getrecommendations! Published in 2017 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01502-17
Abstract: ABSTRACT More-permissive preclinical models may be useful in evaluating antituberculosis regimens for their propensity to select drug-resistant mutants. To evaluate whether acquired rifamycin monoresistance could be recapitulated in mice and, if so, to evaluate the… read more here.
Keywords: isoniazid; immunodeficiency intermittent; rifapentine; rifamycin monoresistance ... See more keywords
Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study
Sign Up to like & getrecommendations! Published in 2021 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01705-21
Abstract: Rifapentine has facilitated treatment shortening for latent tuberculosis infection (LTBI) in combination with isoniazid once weekly for 3 months (3HP) or daily for 1 month (1HP). Our objective was to determine the optimal rifapentine dose for a… read more here.
Keywords: latent tuberculosis; efficacy; tuberculosis infection; rifapentine ... See more keywords
Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.1076266
Abstract: Tuberculosis remains the leading cause of death among people living with HIV. Rifapentine is increasingly used to treat active disease or prevent reactivation, in both cases given either as weekly or daily therapy. However, rifapentine… read more here.
Keywords: rilpivirine; rifapentine; drug drug; drug interaction ... See more keywords